Safety of intravenous thrombolysis for acute XXXX including concomitant @entity5 sufferers - experience from Poland.

@entity1 @entity64 @entity932 @entity548 @entity5 @entity49
BACKGROUND: @entity64 ( @entity64 ), @entity932 and @entity49 can occur as an early and late complication of @entity5 in the clinical course. @entity5 @entity1 are at increased risk for @entity64 from direct and indirect effects of their malignancy. AIMS: The aim of our study was to evaluate the relationship between @entity5 and the long-term outcome, mortality and the presence of @entity548 in @entity1 with acute @entity64 treated with i.v. thrombolysis. METHODS: We retrospectively evaluated the demographic and clinical data of 495 Caucasian @entity1 with acute @entity64 and 40 @entity1 with @entity64 and concomitant @entity5 who were consecutively treated from 2006 to 2013 in two experienced @entity64 centres. RESULTS: In analysed group, there were 7.8% of @entity1 with @entity5 [50.0% male, mean age 72.3      9.3; National Institutes of Health @entity64 Scale - 13 (range 9.5-17)]. @entity5 was diagnosed before i.v.-thrombolysis in 28 (70.0%) @entity1 . After 3  months of follow up, 60% of @entity1 were independent (mRS 0-2) compared with the group of @entity1 without @entity5 - 55% (p  =  0.54), 17.5% died (18.4%; p  =  0.89), 12.4% suffered @entity548 ( @entity548 ) (17.6%; p  =  0.41) and 2.5% experienced SICH (4.4%; p  =  0.56, respectively). Other clinical complications were not found. A multivariate analysis showed no impact of @entity5 on unfavourable outcomes [modified Rankin scale 3-6)] after 3 months (p  =  0.15). CONCLUSION: Intravenous thrombolysis performed in Caucasian @entity64 @entity1 with past or current @entity5 , but not in the course of chemo- and radiotherapy, can be a safe and effective method of treatment. In making decision on the thrombolytic treatment, the risk of @entity548 complications and the life expectancy should be assessed.
